These stocks are cruisin’ … Royal Caribbean Cruises (NYSE: RCL) and Carnival Corp. (NYSE: CCL) both got Strong Buy ratings and price target upgrades this week. In a different sector but similarly hot is Boston Scientific Corp. (NYSE: BSX), which a top-rated analyst believes could see significant upside in the upcoming year. Here’s the story:
1- Royal Caribbean Cruises (NYSE: RCL)
Zen Rating: B (BUY)
Analyst/Firm: James Hardiman / Citigroup
Analyst ranking: Top 13%
Price at writing: $245.52
Price target: $283.00
- Maintaining a Strong Buy rating, Citigroup's James Hardiman raised their price target on Royal Caribbean Cruises (NYSE: RCL) by 10.1% from $257 to $283 on 12/11. See more price targets + ratings on RCL here
- Hardiman told investors that a deep dive into their Consumer Goods (Leisure) sector coverage catalyzed their price target hike.
- According to the analyst, their recent study of the cruise space indicated good trends that will likely continue into 12/2024, "albeit with pockets of Q/Q weakness" in online traffic.
- In spite of a "slight slowdown" following a successful Wave Season earlier this year, consumer interest in cruises remained continuously strong throughout 2023 and into 2024, with indicators indicating stable trends in 2H 2024, Hardiman said.
- The analyst expects projections for cruise companies to keep going up and that multiples will rise somewhat as a result of investors chasing the industry's excellent growth characteristics, relative affordability, low valuation, demographic tailwinds, and tariff-free status.

________________________
A message from our sponsors...
Wall Street Takes Notice of a Young Company's Bombshell Discovery! A young company's fortune may have changed virtually overnight... They've uncovered millions of ounces of high-grade, visible gold in North America. This means low extraction costs and with gold forecasts of $3,000/oz, you can see the potential of this find. Wall Street has already taken notice with analysts calling for a 211% upside! Learn more before the market catches on! Reveal this company here.*
* Thanks to our sponsors for keeping this content free.
________________________
2- Carnival Corp. (NYSE: CCL)
Zen Rating: B (BUY)
Analyst/Firm: James Hardiman / Citigroup
Analyst ranking: Top 13%
Price at writing: $26.58
Price target: $30.00
- Maintaining a Strong Buy rating, Citigroup's James Hardiman raised their price target on Carnival (NYSE: CCL) by 7.1% from $28 to $30 on 12/11. See more price targets + ratings on CCL here
- Hardiman told investors that a deep dive into their Consumer Goods (Leisure) sector coverage catalyzed their price target hike.
- According to the analyst, their recent study of the cruise space indicated good trends that will likely continue into 2024/12, "albeit with pockets of Q/Q weakness" in online traffic.
- In spite of a "slight slowdown" following a successful Wave Season earlier this year, consumer interest in cruises remained continuously strong throughout 2023 and into 2024, with indicators indicating stable trends in 2H 2024, Hardiman said.
- The analyst expects projections for cruise companies to keep going up and that multiples will rise somewhat as a result of investors chasing the industry's excellent growth characteristics, relative affordability, low valuation, demographic tailwinds, and tariff-free status.

3- Boston Scientific Corp. (NYSE: BSX)
Zen Rating: B (Buy)
Analyst/Firm: Joanne Wuensch / Citigroup
Analyst ranking: Top 9%
Price at writing: $90.56
Price target: $107.00
- Maintaining a Strong Buy rating, Citigroup's Joanne Wuensch raised their price target on Boston Scientific (NYSE: BSX) by 9.2% from $98 to $107 on 12/11. See more price targets and ratings on BSX here.
- Wuensch made their price target move on Boston Scientific in a 2025 preview of names in the U.S. Medical Technology sector.
- The analyst said that they added the name to Citigroup's Focus List because they expect the stock's momentum.
- Wuensch explained that, for Boston Scientific, "next year's growth drivers should be a retelling of the 2024 story - continued expansion of Farapulse pulsed-field ablation and Watchman left atrial appendage closure adoption and penetration.

What to Do Next?